Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Cancer Research

• Publication date

  1999-09-15

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 10493518
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemical Cyclin-Dependent Kinase Inhibitors: Therapeutic Implications

  2000cited by this paper
• pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells.

  1999cited by this paper
• Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo.

  1998cited by this paper
• Inhibition of Cyclin D1 Kinase Activity Is Associated with E2F-Mediated Inhibition of Cyclin D1 Promoter Activity through E2F and Sp1

  1998cited by this paper
• The regulation of E2F by pRB-family proteins.

  1998cited by this paper
• Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation

  1998cited by this paper
• Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.

  1998influential reference
• Rapamycin Inhibition of the G1 to S Transition Is Mediated by Effects on Cyclin D1 mRNA and Protein Stability*

  1998cited by this paper
• A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA.

  1998cited by this paper
• A tumor-specific truncated estrogen receptor splice variant enhances estrogen-stimulated gene expression.

  1998cited by this paper
• Increased Expression of Cyclin D2 during Multiple States of Growth Arrest in Primary and Established Cells

  1998cited by this paper
• Glycogen synthase kinase-3 b regulates cyclin D1 proteolysis and subcellular localization

  1998cited by this paper
• Targeting of CDK8 to a promoter-proximal RNA element demonstrates catalysis-dependent activation of gene expression.

  1998cited by this paper
• Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization.

  1998cited by this paper
• Transforming Potential of Dbl Family Proteins Correlates with Transcription from the Cyclin D1 Promoter but Not with Activation of Jun NH2-terminal Kinase, p38/Mpk2, Serum Response Factor, or c-Jun*

  1998cited by this paper
• Cyclin D Expression Is Controlled Post-transcriptionally via a Phosphatidylinositol 3-Kinase/Akt-dependent Pathway*

  1998cited by this paper
• Fos Family Members Induce Cell Cycle Entry by Activating Cyclin D1

  1998cited by this paper
• Alterations of p53, cyclin D1, rb, and H‐ras in human oral carcinomas related to tobacco use

  1998cited by this paper
• Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4

  1997cited by this paper
• Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin’s lymphomas. Functional studies in a cell line (Granta 519)

  1997cited by this paper
• Cyclin-dependent kinases: engines, clocks, and microprocessors.

  1997cited by this paper
• A role for cyclin D3 in the endomitotic cell cycle

  1997cited by this paper
• The targeting of the cyclin D1 oncogene by an Epstein-Barr virus promoter in transgenic mice causes dysplasia in the tongue, esophagus and forestomach

  1997cited by this paper
• Regulation of Cyclin D1 by Calpain Protease*

  1997cited by this paper
• Control of the G1/S transition.

  1997cited by this paper
• Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitro

  1997cited by this paper
• CDK-independent activation of estrogen receptor by cyclin D1.

  1997cited by this paper
• Effects of cyclin D1 overexpression on G1 progression-related events.

  1997cited by this paper
• High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers.

  1997cited by this paper
• The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas.

  1997cited by this paper
• Rac regulation of transformation, gene expression, and actin organization by multiple, PAK-independent pathways

  1997cited by this paper
• The consensus motif for phosphorylation by cyclin D1‐Cdk4 is different from that for phosphorylation by cyclin A/E‐Cdk2.

  1996cited by this paper
• Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2

  1996cited by this paper
• Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

  1996cited by this paper
• How Proteolysis Drives the Cell Cycle

  1996cited by this paper
• Induction of cyclin D1 by simian virus 40 small tumor antigen.

  1996cited by this paper
• Angiotensin II Activation of Cyclin D1-dependent Kinase Activity*

  1996cited by this paper
• Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II.

  1996cited by this paper
• Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer.

  1996cited by this paper
• Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy.

  1996cited by this paper
• Specific transformation abolishes cyclin D1 fluctuation throughout the cell cycle

  1996cited by this paper
• Functional Analysis of the Human Cyclin D2 and Cyclin D3 Promoters (*)

  1996cited by this paper
• Overexpression of cyclin D1 enhances gene amplification.

  1996cited by this paper
• Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

  1996influential reference
• Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts

  1996cited by this paper
• Unscheduled expression of cyclins D1 and D3 in human tumour cell lines

  1996cited by this paper
• Cyclin D1 Expression Is Regulated Positively by the p42/p44MAPK and Negatively by the p38/HOGMAPK Pathway*

  1996cited by this paper
• Cancer Cell Cycles

  1996cited by this paper
• Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer.

  1995cited by this paper
• Transforming p21ras Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions (*)

  1995cited by this paper
• Lack of cyclin D‐Cdk complexes in Rb‐negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product.

  1995cited by this paper
• Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity

  1995cited by this paper
• Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions

  1995cited by this paper
• Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis.

  1995cited by this paper
• Eukaryotic Translation Initiation Factor 4E Regulates Expression of Cyclin D1 at Transcriptional and Post-transcriptional Levels (*)

  1995cited by this paper
• Effects of tumor necrosis factor-alpha on antimitogenicity and cell cycle-related proteins in MCF-7 cells.

  1995cited by this paper
• Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.

  1995cited by this paper
• D-type cyclins.

  1995cited by this paper
• The retinoblastoma protein and cell cycle control.

  1995cited by this paper
• The cell cycle kinases.

  1994cited by this paper
• Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma.

  1994cited by this paper
• Function of a human cyclin gene as an oncogene.

  1994cited by this paper
• PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro.

  1994cited by this paper
• Cell cycle‐related variation and tissue‐restricted expression of human cyclin D1 protein

  1994cited by this paper
• Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.

  1994cited by this paper
• Growth factor-regulated G1 cyclins.

  1994cited by this paper
• Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle.

  1994cited by this paper
• Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice

  1994cited by this paper
• Differential expression and regulation of Cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for Cyclin D1 function in G1 progression.

  1994cited by this paper
• Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts.

  1994cited by this paper
• Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation.

  1994cited by this paper
• Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity.

  1993cited by this paper
• Growth factor regulation of cyclin D1 mRNA expression through protein synthesis-dependent and -independent mechanisms.

  1993cited by this paper
• Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275.

  1992cited by this paper
• Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins.

  1992cited by this paper
• A novel cyclin encoded by a bcl1-linked candidate oncogene

  1991cited by this paper
• Characterization of a candidate bcl-1 gene

  1991cited by this paper
• Human D-type cyclin.

  1991cited by this paper
• bcl-1, t(11;14), and mantle cell-derived lymphomas.

  1991cited by this paper
• Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast.

  1991cited by this paper
• Significance of int-2/hst-1 coamplification as a prognostic factor in patients with esophageal squamous carcinoma.

  1991cited by this paper
• BCL-1 participates in the 11q13 amplification found in breast cancer.

  1990cited by this paper
• Amplification of the int-2 gene in human head and neck squamous cell carcinomas.

  1990cited by this paper
• Basic methods in molecular biology

  1986cited by this paper

• Cyclin-dependent protein kinases and cell cycle regulation in biology and disease

  2025cites this paper
• Molecular mechanisms underlying TXNIP’s anti-tumor role in breast cancer, including interaction with a novel, pro-tumor partner: CAST

  2025cites this paper
• Revisiting 'Hallmarks of Cancer' In Sarcomas

  2024cites this paper
• Flavopiridol inhibits adipogenesis and improves metabolic homeostasis by ameliorating adipose tissue inflammation in a diet-induced obesity model.

  2024cites this paper
• Cyclin-dependent kinase-9 in B-cell malignancies: pathogenic role and therapeutic implications

  2023cites this paper
• Pan Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer

  2023cites this paper
• Promising Role of Phytochemicals in the Prevention and Treatment of Cancer.

  2022cites this paper
• Modulation of Primary Cilia by Alvocidib Inhibition of CILK1

  2022cites this paper
• Cellular Basis of Organotin(IV) Derivatives as Anticancer Metallodrugs: A Review

  2021cites this paper
• Therapeutic Targeting of the General RNA Polymerase II Transcription Machinery

  2020cites this paper
• Stem cell paracrine actions in tissue regeneration and potential therapeutic effect in human endometrium: a retrospective study

  2019cites this paper
• Mitigating Temozolomide Resistance in Glioblastoma via DNA Damage-Repair Inhibition

  2019cites this paper
• Resveratrol is a promising agent for colorectal cancer prevention and treatment: focus on molecular mechanisms

  2019cites this paper
• Flavopiridol's effects on metastasis in KRAS mutant lung adenocarcinoma cells

  2018influential citation
• Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review

  2018cites this paper
• Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma

  2017influential citation
• Cross-talk between p21-activated kinase 4 and ERα signaling triggers endometrial cancer cell proliferation

  2017cites this paper
• Autophagy is essential for flavopiridol‑induced cytotoxicity against MCF‑7 breast cancer cells.

  2017cites this paper
• Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.

  2017cites this paper
• Investigation of the cytotoxic effect of flavopiridol in canine lymphoma cell lines.

  2016cites this paper
• Flavopiridol's antiproliferative effects in glioblastoma multiforme.

  2016cites this paper
• Antiproliferative, Cytotoxic, and Apoptotic Activity of Steroidal Oximes in Cervicouterine Cell Lines

  2016cites this paper
• Over-expression of AURKA, SKA3 and DSN1 contributes to colorectal adenoma to carcinoma progression

  2016cites this paper
• (−)-Hinokinin Induces G2/M Arrest and Contributes to the Antiproliferative Effects of Doxorubicin in Breast Cancer Cells

  2016cites this paper
• Characterization of the cytotoxic activity of [2]rotaxane (TRO-A0001), a novel supramolecular compound, in cancer cells

  2016cites this paper
• Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy

  2016cites this paper
• Anticancer Alkaloids from Trees: Development into Drugs

  2016cites this paper
• The effect of organic anion-transporting polypeptides 1B1, 1B3 and 2B1 on the antitumor activity of flavopiridol in breast cancer cells.

  2015cites this paper
• The Chromone Alkaloid, Rohitukine, Affords Anti-Cancer Activity via Modulating Apoptosis Pathways in A549 Cell Line and Yeast Mitogen Activated Protein Kinase (MAPK) Pathway

  2015cites this paper
• Endogenous and Pharmacological Inhibitors of Cyclin Dependent Kinases in Cell Cycle Regulation of Normal and Cancer Cells

  2015cites this paper
• Essential role of the cGMP/PKG signaling pathway in regulating the proliferation and survival of human renal carcinoma cells.

  2014cites this paper
• Induced growth inhibition, cell cycle arrest and apoptosis in CD133+/CD44+ prostate cancer stem cells by flavopiridol

  2014cites this paper
• Clinical Study A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma

  2014cites this paper
• Refractory Anemia with Excess Blasts-2 Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or A Phase I Trial of Vorinostat and Alvocidib in Patients with

  2013cites this paper
• Effect of mimetic CDK9 inhibitors on HIV-1-activated transcription.

  2013cites this paper
• Cell cycle deregulation in breast cancer subgroups and effects on proliferation, migration and tamoxifen resistance

  2013cites this paper
• Apoptosis in Human Myeloid Leukemia Cells Differentiation and CDKI Expression while Enhancing Disrupts Phorbol 12-Myristate 13-Acetate-induced The Cyclin-dependent Kinase Inhibitor (CDKI) Flavopiridol

  2013cites this paper
• Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity

  2013cites this paper
• Novel Neuroprotective GSK-3β Inhibitor Restricts Tat-Mediated HIV-1 Replication

  2013cites this paper
• Targeting the Cell Cycle for Cancer Treatment and Neuroprotection

  2013cites this paper
• Compound K, a Ginsenoside Metabolite, Inhibits Colon Cancer Growth via Multiple Pathways Including p53-p21 Interactions

  2013cites this paper
• A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2

  2013influential citation
• Synthesis and selective anticancer activity of steroidal glycoconjugates.

  2012cites this paper
• Coffee Polyphenols Change the Expression of STAT5B and ATF-2 Modifying Cyclin D1 Levels in Cancer Cells

  2012cites this paper
• Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

  2012cites this paper
• Cyclin-dependent kinase modulators and cancer therapy.

  2012cites this paper
• Cyclin-Dependent Kinase Modulators and Cancer Therapy

  2012cites this paper
• Inhibitory Effect of Snake Venom on Colon Cancer Cell Growth Through Induction of Death Receptor Dependent Apoptosis

  2012cites this paper
• A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors

  2012cites this paper
• Cyclin-dependent kinase inhibition by flavoalkaloids.

  2012cites this paper
• Dietary Polyphenols and Their Effects on Cell Biochemistry and Pathophysiology 2013

  2012cites this paper
• Role of D-type cyclins in heart development and disease.

  2012cites this paper
• followed by cytosine arabinoside and mitoxantrone for acute leukemias Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol

  2012cites this paper
• A predicted protein, KIAA0247, is a cell cycle modulator in colorectal cancer cells under 5-FU treatment

  2011cites this paper
• Salvage Therapy for Acute Myeloid Leukemia: Current Strategies and Emerging Therapies

  2011cites this paper
• Targeted Therapeutics in Cancer Treatment

  2011cites this paper
• Synthesis and biological evaluation of the glycoside (25R)-3β,16β-diacetoxy-22-oxocholest-5-en-26-yl β-d-glucopyranoside: a selective anticancer agent in cervicouterine cell lines.

  2011cites this paper
• A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway.

  2011cites this paper
• Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.

  2011cites this paper
• Gastroprotective effect of anti-cancer compound rohitukine: possible role of gastrin antagonism and H+ K+-ATPase inhibition

  2011cites this paper
• , 3-kinase pathway preclinical efficacy in myeloma and leukemia via phosphoinositide A small-molecule inhibitor of D-cyclin transactivation displays

  2011cites this paper
• Gene regulation by SMAR1: Role in cellular homeostasis and cancer.

  2011cites this paper
• Chemoprevention in experimental animals

  2011cites this paper
• The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications

  2011cites this paper
• Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms

  2011cites this paper
• Transcription Inhibition as a Therapeutic Target for Cancer

  2011cites this paper
• Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies

  2011cites this paper
• Strategy to induce apoptosis and circumvent resistance in chronic lymphocytic leukaemia.

  2010cites this paper
• Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen

  2010cites this paper
• Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy.

  2010cites this paper
• Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.

  2010cites this paper
• Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

  2010cites this paper
• microRNA machinery is an integral component of drug-induced transcription inhibition in HIV-1 infection

  2010cites this paper
• Transcription elongation takes central stage: The P-TEFb connection

  2010cites this paper
• Genetische Grundlagen der Kanzerogenese

  2010cites this paper
• Chloroform extract from Moricandia arvensis inhibits growth of B16‐F0 melanoma cells and promotes differentiation in vitro

  2010cites this paper
• Synthesis of the steroidal glycoside (25R)-3β,16β-diacetoxy-12,22-dioxo-5α-cholestan-26-yl β-D-glucopyranoside and its anti-cancer properties on cervicouterine HeLa, CaSki, and ViBo cells.

  2010cites this paper
• Cancer esearch apeutics , Targets , and Chemical Biology ponses in Mantle Cell Lymphoma Cells to SNS-032 R end on the Biological Context of Each Cell Line

  2010cites this paper
• Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition

  2010cites this paper
• A Phase I Study of Flavopiridol in Combination With Gemcitabine and Irinotecan in Patients With Metastatic Cancer

  2010cites this paper
• Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.

  2009cites this paper
• Cytotoxic Activity of Isoliquiritigenin towards CCRF‐CEM Leukemia Cells and its Effect on DNA Damage

  2009cites this paper
• CELL CYCLE PHARMACOLOGY, ANTIPROLIFERATION, AND APOPTOSIS

  2009cites this paper
• Identification and characterization of molecular targets of natural products by mass spectrometry.

  2009cites this paper
• Influence of dietary resveratrol on early and late molecular markers of 1,2-dimethylhydrazine-induced colon carcinogenesis.

  2009cites this paper
• CDK Inhibitors as Anticancer Agents

  2008cites this paper
• Synergistic Inhibition of ErbB Signaling by Combined Treatment with Seliciclib and ErbB-Targeting Agents

  2008cites this paper
• Trichosanthes kirilowii tuber extract induces G2/M phase arrest via inhibition of tubulin polymerization in HepG2 cells.

  2008cites this paper
• Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer.

  2008cites this paper
• Chapter 22 CDK Inhibitors in Multiple Myeloma

  2008cites this paper
• Induction of apoptosis in Jeko-1 mantle cell lymphoma cell line by resveratrol: a proteomic analysis.

  2008cites this paper
• Nucleophosmin interacts with HEXIM1 and regulates RNA polymerase II transcription.

  2008cites this paper
• Induction of apoptosis by the kinase inhibitor flavopiridol in human ovarian cancer cell lines

  2008cites this paper
• The Cell Cycle

  2008cites this paper
• CDK Inhibitors in Multiple Myeloma

  2008cites this paper
• Targeting cell cycle kinases and kinesins in anticancer drug development

  2007cites this paper
• In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00

  2007cites this paper
• Novel therapeutic targets in mantle cell lymphoma

  2007cites this paper
• Inhibiting cell cycle progression reduces reactive astrogliosis initiated by scratch injury in vitro and by cerebral ischemia in vivo

  2007cites this paper
• Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression.

  2007cites this paper